Rheumatology International

, Volume 31, Issue 4, pp 457–461 | Cite as

Serum chemokines in patients with rheumatoid arthritis treated with etanercept

  • Piotr Adrian Klimiuk
  • Stanislaw Sierakowski
  • Izabela Domyslawska
  • Justyna Chwiecko
Original Article


Chemokines promote leucocyte traffic into the synovium, leading to the initiation and progression of the rheumatoid arthritis (RA). The aim of the study was to determine the effects of etanercept, a soluble tumour necrosis factor receptor (sTNFr), on the serum chemokines levels in patients with active RA. Patients were treated with 50 mg of subcutaneous injection of etanercept per week and methotrexate (10–25 mg/week). Serum levels of interleukin-8 (IL-8), RANTES (regulated upon activation, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 (MCP-1) were assessed by ELISA at months 0, 3, 6, 9 and 12, prior to injection. 3-month treatment with etanercept diminished serum concentrations of IL-8, RANTES and MCP-1 (P < 0.05, P < 0.01 and P < 0.001, respectively). Subsequent etanercept administrations prolonged decrease in serum chemokines levels and in the case of IL-8 even intensified the reduction of its concentration in serum. These changes were accompanied by significant decrease of disease activity score (DAS28) (in all cases P < 0.001). Prior to the first etanercept administration, serum concentrations of studied chemokines correlated with markers of RA activity such as the erythrocyte sedimentation rate (ESR) and DAS28. Following next drug injection such associations were less or not significant. Therapy with etanercept and MTX not only caused a clinical improvement but also diminished serum chemokines levels in RA patients. Further treatment with etanercept sustained chemokines suppression.


Chemokines IL-8 RANTES MCP-1 Rheumatoid arthritis Etanercept 



Study was support by the grant (3-60766L) from Medical University of Bialystok, Poland.


  1. 1.
    Tarrant TK, Patel DD (2006) Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 13:1–14PubMedCrossRefGoogle Scholar
  2. 2.
    Vergunst CE, van de Sande MG, Lebre MC, Tak PP (2005) The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 34:415–425PubMedCrossRefGoogle Scholar
  3. 3.
    Haringman JJ, Ludikhuize J, Tak PP (2004) Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 63:1186–1194PubMedCrossRefGoogle Scholar
  4. 4.
    Szekanecz Z, Pakozdi A, Szentpetery A, Besenyei T, Koch AE (2009) Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci 1:44–51Google Scholar
  5. 5.
    Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM (1992) Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772–779PubMedCrossRefGoogle Scholar
  6. 6.
    Pulsatelli L, Dolzani P, Piacentini A, Silvestri T, Ruggeri R, Gualtieri G, Meliconi R, Facchini A (1999) Chemokine production by human chondrocytes. J Rheumatol 26:1992–2001PubMedGoogle Scholar
  7. 7.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2002) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 41:78–87PubMedCrossRefGoogle Scholar
  8. 8.
    Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, Kraan MC, Youssef PP (2001) Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology 40:988–994PubMedCrossRefGoogle Scholar
  9. 9.
    Takahashi Y, Kasahara T, Sawai T, Rikimaru A, Mukaida N, Matsushima K, Sasaki T (1999) The participation of IL-8 in the synovial lesions at an early stage of rheumatoid arthritis. Tohoku J Exp Med 188:75–87PubMedCrossRefGoogle Scholar
  10. 10.
    Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP (2006) Chemokine and chemokine receptor expression in paired peripheral blond mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 65:294–300PubMedCrossRefGoogle Scholar
  11. 11.
    Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602PubMedCrossRefGoogle Scholar
  12. 12.
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932–1939PubMedCrossRefGoogle Scholar
  13. 13.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  14. 14.
    van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S (2006) TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–1074PubMedCrossRefGoogle Scholar
  15. 15.
    van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D (2006) Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 65:1478–1483PubMedCrossRefGoogle Scholar
  16. 16.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2006) Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:529–533PubMedGoogle Scholar
  17. 17.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  18. 18.
    Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRefGoogle Scholar
  19. 19.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Skowronski J, Cylwik JP, Cylwik B, Chwiecko J (2005) Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J Rheumatol 32:1666–1672PubMedGoogle Scholar
  20. 20.
    Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J (2000) Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 6:71–79PubMedCrossRefGoogle Scholar
  21. 21.
    Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN (1995) Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 101:398–407PubMedCrossRefGoogle Scholar
  22. 22.
    Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE (1998) RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol 89:44–53PubMedCrossRefGoogle Scholar
  23. 23.
    Ellingsen T, Buus A, Moller BK, Stengaard-Pedersen K (2000) In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters. Scand J Rheumatol 29:216–221PubMedCrossRefGoogle Scholar
  24. 24.
    Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C (1999) Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol 17:419–425PubMedGoogle Scholar
  25. 25.
    Kageyama Y, Kobayashi H, Kato N, Shimazu M (2009) Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis. Mod Rheumatol 19:372–378PubMedCrossRefGoogle Scholar
  26. 26.
    Ellingsen T, Buus A, Stengaard-Pedersen K (2001) Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol 28:41–46PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Piotr Adrian Klimiuk
    • 1
  • Stanislaw Sierakowski
    • 1
  • Izabela Domyslawska
    • 1
  • Justyna Chwiecko
    • 1
  1. 1.Department of Rheumatology and Internal DiseasesMedical University of BialystokBialystokPoland

Personalised recommendations